Singapore, March 18, 2008: Glenmark Pharmaceuticals Inc (GPI), the US subsidiary of Glenmark Pharmaceuticals Limited (Glenmark), one of the leading, integrated specialty pharmaceutical and high-quality generic companies from India, has commenced marketing and distribution of five Clobetasol Propionate dermatology products in the US market.

 

The GPI has acquired the US marketing rights for a line of Clobetasol Propionate products which include - Cream, E Cream, Ointment, Gel and Topical Solution through an US based pharmaceutical development company.

 

Clobetasol Propionate is used to treat diseases such as eczema and psoriasis, where it is used on the scalp and body. It is also dispensed to counter auto-immune presentations, such as Alopecia areata (hair loss due to auto-immune diseases) and Lichen planus (auto immune skin nodules). The total sales for the five above mentioned Clobetasol Propionate products in the 12 month period ending December 2007 were in excess of US$ 28 million, as per the IMS Health report.

 

This dermatology portfolio marks Glenmark’s entry into the US semisolid product market. The GPI plans to launch an additional 11 dermatological products in the next 12 months. Based on these recent launches, GPI now has a portfolio of 28 generic products for the US market and currently it has over 35 ANDAs undergoing US FDA approval process/launch.